T1 Organism 120 128 patients
T2 Gene 689 740 prostatic specific antigen and alkaline phosphatase
T3 Biomarker 566 584 urinary creatinine
T4 Biomarker 1442 1454 pyridinoline
T5 Condition 1518 1540 metastatic bone tumors
T7 Biomarker 455 467 pyridinoline
T9 Biomarker 1166 1178 pyridinoline
T10 Organism 120 127 patient
T12 Biomarker 911 923 pyridinoline
T13 Organism 945 952 patient
T14 Biomarker 1442 1476 pyridinoline and deoxypyridinoline
T15 Organism 193 200 patient
T18 Condition 78 82 bone
T19 Gene 1035 1061 prostatic-specific antigen
T20 Intervention 1381 1397 bone scintigrams
T21 Biomarker 262 274 pyridinoline
T23 Biomarker 1343 1360 deoxypyridinoline
T24 Biomarker 284 296 pyridinoline
T25 Organism 945 953 patients
T26 Intervention 1569 1585 bone scintigrams
T28 Condition 1529 1533 bone
T29 Protein 485 495 ion-paired
T30 Biomarker 42 59 deoxypyridinoline
T31 Intervention 773 789 bone scintigrams
T32 Organism 354 361 patient
T33 Condition 134 149 prostate cancer
T34 Condition 1569 1573 bone
T35 Condition 962 966 bone
T36 Condition 1004 1008 bone
T37 Condition 1518 1539 metastatic bone tumor
T38 Biomarker 433 467 Pyridinoline and deoxypyridinoline
T39 Biomarker 25 37 pyridinoline
T40 Biomarker 626 660 pyridinoline and deoxypyridinoline
T41 Intervention 837 848 bone lesion
T42 Organism 990 998 patients
T43 Biomarker 1326 1338 pyridinoline
T44 Biomarker 1147 1159 pyridinoline
T48 Organism 193 201 patients
T49 Biomarker 889 901 pyridinoline
T50 Condition 175 179 bone
T54 Biomarker 1326 1360 pyridinoline and deoxypyridinoline
T55 Organism 1593 1600 patient
T56 Condition 245 249 bone
T57 Biomarker 1161 1178 deoxypyridinoline
T58 Condition 164 185 metastatic bone tumor
T60 Organism 354 362 patients
T61 Biomarker 262 296 pyridinoline and deoxypyridinoline
T62 Condition 216 220 bone
T63 Condition 1381 1385 bone
R1 Relation Arg1:T56 Arg2:T24
R2 Relation Arg1:T62 Arg2:T24
R3 Relation Arg1:T62 Arg2:T56
